AIMC Topic: Sodium-Glucose Transporter 2 Inhibitors

Clear Filters Showing 1 to 6 of 6 articles

Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials.

Circulation. Heart failure Nov 16, 2024
BACKGROUND: Medical record review by a physician clinical events committee is the gold standard for identifying cardiovascular outcomes in clinical trials, but is labor-intensive and poorly reproducible. Automated outcome adjudication by artificial i...
Sodium-Glucose Transporter 2 Inhibitors Heart Failure Benzhydryl Compounds Clinical Trials as Topic Reproducibility of Results Hospitalization Male Stroke Volume Natural Language Processing Glucosides Artificial Intelligence Electronic Health Records Female Humans
View on PubMed DOI

Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.

Scientific reports Jun 8, 2021
The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear. Here we aimed to use artificial int...
Models, Cardiovascular Sodium-Hydrogen Exchanger 1 Humans Artificial Intelligence Sodium-Glucose Transporter 2 Inhibitors Heart Failure Stroke Volume Sodium-Glucose Transporter 2 Benzhydryl Compounds Myocardium Glucosides
View on PubMed DOI

Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study.

Diabetes, obesity & metabolism Aug 1, 2025
AIMS: A precision medicine approach in type 2 diabetes (T2D) needs to consider potential treatment risks alongside established benefits for glycaemic and cardiometabolic outcomes. Considering five major T2D drug classes, we aimed to describe variatio...
Adult Male Humans Middle Aged Precision Medicine Female Aged Sodium-Glucose Transporter 2 Inhibitors Sulfonylurea Compounds Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide-1 Receptor Agonists Diabetes Mellitus, Type 2 Hypoglycemic Agents United Kingdom
View on PubMed DOI

A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease.

Cardiovascular diabetology May 15, 2025
BACKGROUND: Individuals with diabetic kidney disease (DKD) often suffer cardiac and kidney events. We sought to develop an accurate means by which to stratify risk in DKD.
Humans Machine Learning Female Reproducibility of Results Risk Factors Decision Support Techniques Biomarkers Prognosis Diabetic Nephropathies Predictive Value of Tests Heart Diseases Heart Disease Risk Factors Sodium-Glucose Transporter 2 Inhibitors Middle Aged Aged Risk Assessment Male Time Factors Cardiovascular Diseases
View on PubMed DOI

Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?

BMJ open diabetes research & care Dec 1, 2019
OBJECTIVE: This study evaluated the characteristics of new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) in clinical practice to assess the applicability of the findings from clinical trials (Empagliflozin, Cardiovascular Outcomes and ...
Benzhydryl Compounds Practice Patterns, Physicians' Bridged Bicyclo Compounds, Heterocyclic Observational Studies as Topic Male Glycated Hemoglobin Cardiovascular Diseases Glucosides Sodium-Glucose Transporter 2 Inhibitors Middle Aged Humans Aged Blood Glucose Canagliflozin Retrospective Studies Aged, 80 and over Cohort Studies Clinical Trials as Topic Female Adult Diabetes Mellitus, Type 2 Diabetic Angiopathies
View on PubMed DOI

Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.

Reviews in cardiovascular medicine Jun 30, 2018
In this systematic review, we sought to summarize the 3 recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials (Dapagliflozin Effect on CardiovasculAR Events (DECLARE-TIMI 58), Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, ...
Treatment Outcome Health Status Kidney Diseases Randomized Controlled Trials as Topic Cause of Death Humans Glucosides Research Design Comorbidity Biomarkers Benzhydryl Compounds Sodium-Glucose Transporter 2 Blood Glucose Risk Factors Canagliflozin Diabetes Mellitus, Type 2 Cardiovascular Diseases Sodium-Glucose Transporter 2 Inhibitors
View on PubMed DOI
Popular Topics
Recent Journals